UNC Kidney Center
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nachman, Patrick H
GOOD-IDES-02, NCT05679401: A Study With Imlifidase in Anti-GBM Disease

Active, not recruiting
3
50
Europe, US, RoW
Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids
Hansa Biopharma AB
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
06/25
11/26
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
NEPTUNE, NCT01209000: Nephrotic Syndrome Study Network

Recruiting
N/A
1200
Canada, US
Kidney Biopsy
University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
06/26
06/26
Derebail, Vimal
GOOD-IDES-02, NCT05679401: A Study With Imlifidase in Anti-GBM Disease

Active, not recruiting
3
50
Europe, US, RoW
Imlifidase, IdeS, HMED-IdeS, Plasma exchange (PLEX), PE, Cyclophosphamide (CYC), Glucocorticoids
Hansa Biopharma AB
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
06/25
11/26
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
NCT03277547: Kidney Function in Sickle Cell Anemia

Active, not recruiting
N/A
300
US
Kenneth Ataga MD, Ohio State University, University of North Carolina
Sickle Cell Disease, Kidney Failure, Chronic
06/25
12/25
NCT03906227: Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

Suspended
N/A
40
US
ENUMERATION OF CD5+ B Cells
University of North Carolina, Chapel Hill, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ANCA Associated Vasculitis
02/25
02/25

Download Options